Healthcare stocks were steady premarket Monday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) down a slight 0.1%.
Novo Nordisk (NVO) is facing shareholder calls to develop new medicines and pursue acquisitions so that it could lower its dependence on its popular weight-loss treatments, the Financial Times reported, citing the company's investors. Shares of Novo Nordisk were down 4.7% pre-bell.